logo
Five years on from the pandemic, long Covid remains a neglected public health legacy

Five years on from the pandemic, long Covid remains a neglected public health legacy

Yahoo20-03-2025

This month marks the fifth anniversary of the pandemic. No one was untouched by its effects, but for the majority of the population it is long forgotten, a memory they would rather erase.
However, there is a major neglected public health legacy that continues to affect large numbers of the population half a decade later: long Covid.
With an estimated 2.9 per cent of the UK population affected (2.2million at its peak, and 400 million globally), it is no small legacy, despite a former PM declaring it b-----t which he scrawled across a government memo on the subject in 2020.
Deciding the pandemic was over, departments of the former Health Protection Agency that were monitoring numbers were disbanded, thus ending reliable data collection nearly two years ago: a whitewashing of a very real and significant illness. The country moved on, but many of us with long Covid have been unable to.
Long Covid (or more accurately Post-Covid-19 Syndrome) is an umbrella term that encompasses a myriad of symptoms that largely fall into three phenotypes/groups based on clinical presentation.
Two hundred symptoms have been described with evidence of damage in 10 different organ systems, that can lead to severe and protracted impairment of function.
This diverse presentation can prove a diagnostic challenge, and to date there is no single diagnostic test. Nevertheless, the resulting burden of illness is high for both the individual and their families. It also has wider societal ramifications on the economy, with many of those affected not able to contribute as they had done previously. They also add to the already overburdened health service.
Our understanding of long Covid has come a long way since 2020 when increasing numbers of people not recovering from seemingly mild acute Covid-19 infections were presenting to their GPs. Many were dismissed as being histrionic, with their symptoms of breathing problems and rapid heart rates attributed to anxiety in response to lockdowns and the Pandemic, rather than the damage they had following infection with the virus.
In 2021, millions of pounds were poured into setting up dedicated clinics and research trials to try and understand the multitude of symptoms that seemed to follow acute infection, with the global scientific community coming together in an unprecedented way.
Slowly we are gaining a better understanding of the illness as studies from around the globe yield results, but the jigsaw of long Covid still has many pieces missing. As yet there is no unifying underlying mechanism, and it is likely that several mechanisms will account for the symptoms and damage occurring after infection.
But translating results into clinical care still has a long way to go. The Stimulate ICP and Legacy trials are due to yield answers in the coming months, with the former looking at 3 potential repurposed drugs, which are easily available to GPs to prescribe should any of them prove to be beneficial.
Ongoing research will bring more answers, but many of the grants awarded have not been renewed, and with the NHS capacity stretched, many long Covid clinics have had their funding cut, and some disbanded. From the outset medical care has been a postcode lottery, with many never seen at a long Covid clinic.
Whilst there remains an absence of any proven definitive treatment for the illness, adjunctive therapies that offer benefit have come to light. One such social prescribing intervention developed in 2020 is the English National Opera (ENO) Breathe programme for long Covid which was developed by the ENO in conjunction with doctors from Imperial College.
It uses singing techniques for breathing retraining to aid recovery following Covid-19, with its proven benefits published in the Lancet, and WHO's endorsement of it lending further weight. To date more than 4,000 of us have been through the programme – being creative in how to manage an illness when there is no hard scientific evidence for what to do or treat with, has been key.
Similar programmes have been set up around the UK and in other countries. In the Uk, you have to be referred by a long Covid NHS clinic.
With the lack of help through the usual NHS channels, many have turned to the plethora of unregulated treatments being offered at various private clinics. Lured with the seductive promise of 'we can get you better', people are prepared to part with large sums of money when nothing else is available: being offered a glimmer of hope when living in limbo in the uncharted territory of a new condition.
A huge lucrative economy has sprung up and continues to flourish offering such hopes and promises, and although anecdotally some have found benefit, most things being offered as 'treatments' lack evidence of efficacy. These have varied from the innocuous retreat centres offering an holistic approach to well-being with yoga, mud baths, mindfulness and Ozone therapy in beautiful rural or Alpine settings (prices range from between £3,000 and £17,000 a week), to those offering more invasive, but unproven, treatments with potentially serious side effects, such as (apheresis) blood washing, plasmapheresis (removal of antibodies), intravenous vitamins and triple anticoagulants.
Hyperbaric oxygen therapy, vitamin supplements, micronutrients, and antivirals are often additionally offered at further cost, with people spending anywhere between £10,000 and £50,000 in various clinics around the globe (both in Europe, and further afield in Thailand and South Africa). These eye-watering amounts are unaffordable to most, but some are prepared to spend their life savings, seriously damaging their already fragile bank balances.
It may be that at a later date some of these 'treatments' may prove to be beneficial, but rigorous clinical trials and regulation are needed to protect a vulnerable population who are willing to try anything to get better: doing something proactive provides agency.
Post-viral conditions have a long history of being neglected and poorly understood, and there are many that have the potential for long lived sequelae, such as SARS, influenza, Epstein Barr Virus (the cause of glandular fever), Ebola. Some sequelae may only last a few months, but others seem to have a natural life span of three or five years.
With funding cuts to long Covid clinics, some have pooled resources and manpower with pre-existing clinics for Chronic Fatigue Syndrome (CFS/ME). These have historically been poorly funded, but they have the expertise to help in managing some of the common symptoms such as post-exertional malaise.
Whilst the two conditions differ, there is overlap of some symptoms, and as research further unpicks the underlying mechanisms for long Covid these may prove to be applicable to other post-viral conditions. No other post-viral condition has had so much longitudinal data collected on it in large trials. For too long those with CFS have been neglected. Let's hope that the long Covid story will have positive ramifications for other neglected post viral conditions, desperate for some hope and care.
Some with long Covid, like myself, are getting better with time, some improving by learning how to manage their symptoms, and some have found that using repurposed drugs to manage particular symptoms can get them back to an acceptable level of functioning. Those lucky enough to be under the care of a long Covid clinic are not promised a cure: there is no magic bullet.
Current approaches to care are symptomatic and supportive, offering a needs-based service. Clinics aim is to help people manage their symptoms to a level that they are able to function better, and to return to work. Many have fully recovered, but hard data on how many have and the time frame to do so is lacking because most are discharged when they are at what is deemed to be an acceptable level of functioning.
For many just being heard for the first time, rather than being dismissed, or told their illness is all in their head can be a major start. This is a very real illness. But given the diverse presentations of the illness, there is no one size fits all management plan. Each management strategy has to be individualised.
So where are we five years on? Whilst our understanding has improved dramatically, we still have a long way to go. There is no unifying mechanism underlying the illness, and it is likely that it will be a combination of things. There is no single diagnostic test, and diagnostic criteria are wide and can prove complex to define. There is no definitive treatment, but we are certainly better at managing the condition and helping people get on the path of recovery back to a level that they can manage their everyday lives better and return to work.
For those affected it can be a long and very rocky road of recovery; I feel I'm finally coming off the physical, mental and emotional long Covid rollercoaster, but for many, half a decade later the effects of the pandemic are far from over.
Dr Joanna Herman is a Consultant in Infectious Diseases and freelance medical journalist
Protect yourself and your family by learning more about Global Health Security
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

Yahoo

time2 hours ago

  • Yahoo

A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms

A new COVID variant known as NB.1.8.1 has made landfall in the United States. The variant, which was first detected in China this past January, currently accounts for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks ago. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. To date, only 20 NB.1.8.1 sequences have been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women Trump's FDA Has Axed COVID Boosters For Most People — And Medical Experts Are Deeply Worried New Trump Vaccine Policy Limits Access To COVID Shots

Beyond MAHA: Defeating obesity requires a new strategy
Beyond MAHA: Defeating obesity requires a new strategy

The Hill

time2 hours ago

  • The Hill

Beyond MAHA: Defeating obesity requires a new strategy

Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons.

China's COVID-19 Infections Jumped by 160 Percent in May
China's COVID-19 Infections Jumped by 160 Percent in May

Epoch Times

time3 hours ago

  • Epoch Times

China's COVID-19 Infections Jumped by 160 Percent in May

COVID-19 cases in China increased more than 160 percent in May, according to the latest official data from the Chinese communist regime. But Chinese residents across the country continue to report to The Epoch Times and on social media that they believe the situation is more serious than what authorities have acknowledged. The Chinese Centers for Disease Control and Prevention (China CDC) released its national COVID-19 epidemic data for May on June 5, reporting 440,662 cases, including 606 severe cases and seven deaths, soaring above April's 168,507 cases, 340 severe cases, and nine deaths.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store